Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in:

06-09-2024 | Acute Lymphoblastic Leukemia | Guideline

JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL

Authors: Yoshihiro Hatta, Koji Izutsu, Makoto Onizuka, Nobuaki Dobashi, Fumihiko Hayakawa, Etsuko Yamazaki

Published in: International Journal of Hematology | Issue 4/2024

Login to get access

Excerpt

Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) are both neoplasms derived from lymphoid progenitor cells and are considered to be essentially the same disease. Patients with a high proportion of lymphoblasts in the bone marrow are considered to have ALL and patients with a predominant mass in the lymphoid tissues and little bone marrow involvement are considered to have LBL. The distinction between the two is not always clear, but ALL is typically diagnosed when the percentage of lymphoblasts in the bone marrow is 25% or higher. …
Metadata
Title
JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL
Authors
Yoshihiro Hatta
Koji Izutsu
Makoto Onizuka
Nobuaki Dobashi
Fumihiko Hayakawa
Etsuko Yamazaki
Publication date
06-09-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology / Issue 4/2024
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03836-7

Other articles of this Issue 4/2024

International Journal of Hematology 4/2024 Go to the issue

Progress in Hematology

Metabolic dependencies of acute myeloid leukemia stem cells

Case Report

Bilateral development of biclonal ocular adnexal marginal zone lymphoma at a 2-year interval

Original Article

Detection of factor XIII inhibitors in 33 patients with autoimmune factor XIII deficiency in Japan

Case Report

Trametinib for a child with refractory Rosai–Dorfman–Destombes disease harboring a novel somatic mutation in MAP2K1

Original Article

A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial)

Rapid Communication

Pathological landscape of tumor flare reaction to epcoritamab treatment

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

Read more

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

Live event concluded

In this webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version
Image Credits